Not a Lexis Advance subscriber? Try it out for free.


Mealey's IP/Tech - Post-Grant Review Petitioner: Cancer Treatment Patent Is Obvious

ALEXANDRIA, Va. - In a Nov. 11 petitioner reply filed with the Patent Trial and Appeal Board, a petitioner for post-grant review (PGR) of a cancer treatment patent maintains its position that the claimed technology suffers from a lack of enablement (Genome & Company v. University of Chicago, No. PGR2019-00002, PTAB).
Find full version on lexis Advance®